| Brand Name | Medinova Biosciences |
|---|---|
| Industry | Pharmaceutical Distribution |
| Business Category | Pharmacies / PCD Pharma Franchise |
| Founded Year | 2020 |
| Franchise Started | 2022 |
| Total Franchise Outlets | 50–100 |
| Estimated Investment | INR 10,000 – 50,000 |
| Franchise Fee | Typically structured within product purchase or onboarding agreements |
| Royalty Fee | Commonly not charged separately in PCD pharma models; earnings are margin-based |
| Space Requirement | 100 – 200 Sq.ft |
| Staff Requirement | Small distribution-focused team |
| Expected Payback Period | 1–2 Years |
Medinova Biosciences is a pharmaceutical company operating in the PCD pharma franchise segment, focused on manufacturing and distributing a range of medicinal products across multiple therapeutic categories. The franchise model is built around localized distribution, where partners market and supply medicines within assigned territories.
The business operates as a distribution-driven pharmaceutical model. Franchise partners procure products from the company and supply them to pharmacies, clinics, and healthcare providers within their territory.
Day-to-day operations include building relationships with doctors and retailers, managing inventory, and ensuring timely product availability. Revenue is generated through the margin between procurement cost and selling price across various pharmaceutical products.
Franchise partners handle a diversified pharmaceutical portfolio, which may include:
This diversified product mix allows franchisees to cater to different healthcare demands within their territory.
This structure reflects a PCD pharma franchise model, where local market penetration is driven by individual distributors.
| Estimated Investment | INR 10,000 – 50,000 |
|---|---|
| Primary Cost Components | Initial product stock, basic storage setup, and local marketing expenses |
| Franchise Fee | Often embedded in initial product purchase or onboarding |
| Royalty | In PCD pharma systems, ongoing royalties are typically replaced by product-based margins |
The low investment requirement positions this as an entry-level pharmaceutical distribution opportunity.
| Space Requirement | 100 – 200 sq.ft |
|---|---|
| Location Preference | Accessible commercial or residential-commercial areas for storage and dispatch |
| Infrastructure Needs | Basic storage racks, inventory management system, and transportation access |
| Staffing | Minimal; often operated by the owner with limited support staff |
Support systems generally include:
These systems help franchisees build and maintain consistent distribution networks.
Revenue is generated through product distribution margins. Key factors influencing earnings include:
The payback period of around 1–2 years reflects gradual scaling based on relationship-building in the healthcare ecosystem.
The company began operations in 2020 and introduced its franchise model in 2022. With a growing network of 50–100 outlets, the expansion strategy focuses on increasing territorial coverage through distributor partnerships across multiple regions.
Medinova Biosciences follows a multi-therapy distribution approach, allowing franchise partners to serve both general and specialized healthcare segments. Unlike single-category pharma distributors, this model enables broader market reach by combining OTC products, generics, and specialty medicines within one distribution framework.
The investment ranges from INR 10,000 to 50,000, mainly covering initial product inventory and basic operational setup. Since this is a distribution-based model, capital is primarily used to purchase stock and initiate local sales activities.
The franchise operates as a pharmaceutical distribution network. Partners procure medicines from the company and supply them to doctors, pharmacies, and clinics within a defined territory. Revenue is generated through margins on product sales.
A compact space of around 100 to 200 square feet is sufficient. This space is mainly used for storing pharmaceutical products and managing dispatch operations rather than customer-facing retail activities.
The expected payback period is approximately 1 to 2 years. Returns depend on how quickly the franchise partner builds a network of healthcare providers and achieves consistent product demand in the assigned territory.
Investors can apply by contacting the company, selecting a territory, and completing onboarding formalities. The process typically includes initial product purchase, receiving marketing materials, and starting distribution operations within the assigned area. ## 14. Similar Franchise Opportunities